Meridian Bioscience, Inc. reported unaudited earnings results for the first quarter ended December 31, 2016. For the quarter, net revenues were $46,809,000 against $47,160,000 a year ago. Operating income was $10,085,000 against $13,586,000 a year ago. Earnings before income taxes were $9,659,000 against $13,699,000 a year ago. Net earnings were $6,279,000 against $8,893,000 a year ago. Net earnings per diluted common share were $0.15 against $0.21 a year ago.

For the full year ending September 30, 2017, management now expects net revenues to be in the range of $193 million to $199 million and per share diluted earnings to be between $0.64 and $0.69.  Prior guidance was for revenues in the range of $205 million to $210 million and per share diluted earnings of $0.81 to $0.85. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.4 million at fiscal 2016 year end to approximately 42.6 million at fiscal 2017 year end.